Home > News > Veristat strengthens its long standing relationship with aegerion pharmaceuticals

1 min read

Veristat Strengthens Its Long-Standing Relationship with Aegerion Pharmaceuticals

Veristat, a full service Clinical Research Organization (CRO), announced today the signing of a Preferred Provider Agreement (PPA) with Aegerion Pharmaceuticals Inc. (“Aegerion”), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases.  Veristat has assisted Aegerion with US Food and Drug Administration, EU Market Authorization Application, and Japan Food and Drug Administration submission projects over the past 5 years.

Veristat will offer Aegerion clinical trial support including statistical consulting, biostatistical analysis, clinical data management, clinical monitoring, SAS programming, clinical protocol and study report writing, project management and the preparation of regulatory submission documents.

“Veristat has been a strong and dedicated collaborative partner and an extension of our project teams,” said Pamela Foulds, MD, Vice President of Clinical Development at Aegerion Pharmaceuticals.

“Veristat is thrilled to progress to this next phase in our working relationship with Aegerion,” stated Barbara Balser, VMD, Chief Scientific Officer at Veristat. “We feel like a true partner to Aegerion and are eager to continue to deliver quality expertise and services for their marketing applications.”

2 min read

Meet Veristat at the ASCO Annual Meeting

May 5, 2026  Veristat Events

May 29 - June 2, 2026 | Chicago, IL

▶️ At the Forefront of Oncology Progress 

Veristat is pleased to attend the ASCO...

1 min read

Connect with Veristat at OCT East Coast

Apr 30, 2026  Veristat Events

May 12-13, 2026 – New Brunswick, NJ

⚛️ Where Clinical Operations Meet Real-World Execution

Veristat is pleased to...